La génomique dans l’Espace Européen de la Recherche Le 6ème programme cadreLe 6ème programme...
Preview:
Citation preview
- Slide 1
- La gnomique dans lEspace Europen de la Recherche Le 6me
programme cadreLe 6me programme cadre Le contexte politique
- Slide 2
- Slide 3
- FP5/QoL : mio 2.2 FP6/TP1+TP5 : mio 3.0 1800 Projects~ 400 TI ~
200 NI 80% 20% LESS with MORE : less projects, higher focussing but
more organisation implied
- Slide 4
- 5th Framework Programme (1998 - 2002) The 6th Framework
Programme (2002 - 2006) Quality of Life programme Thematic Priority
1 or 5 Public dialogue Innovation and technology transfer
initiatives Innovation and technology transfer initiatives wet
science wet science Bioethics Research Bioethics Research
Socio-economic research Socio-economic research Ethics Public
dialogue Innovation and competitiveness wet science Academia -
Industry - Engineering Regulation and governance Fragmentation
- Slide 5
- Life Sciences, Genomics and Biotechnology for Health (FP6) Life
Sciences, Genomics & biotechnology for health Advanced Genomics
and its applications for health (1100 M) Fundamental knowledge and
basic tools for functional genomics in all organisms (Structural
genomics; proteomics; comparative genomics; bioinformatics;
Multidisciplinary genomics approaches to basic biological
processes) Application of knowledge and technologies in the field
of genomics and biotechnology for health (Technology platforms;
support to start-up companies) Advanced Genomics and its
applications for health (1100 M) Fundamental knowledge and basic
tools for functional genomics in all organisms (Structural
genomics; proteomics; comparative genomics; bioinformatics;
Multidisciplinary genomics approaches to basic biological
processes) Application of knowledge and technologies in the field
of genomics and biotechnology for health (Technology platforms;
support to start-up companies) Combating major diseases (1155 M)
Application-oriented approach to medical genomics knowledge
(Cardiovascular disease, diabetes and rare diseases ; resistance to
antibiotics ; Studying the brain and combating diseases of the
nervous system ; Studying human development and the ageing process)
Broader biomedical approach (cancer, poverty-related infectious
diseases) Combating major diseases (1155 M) Application-oriented
approach to medical genomics knowledge (Cardiovascular disease,
diabetes and rare diseases ; resistance to antibiotics ; Studying
the brain and combating diseases of the nervous system ; Studying
human development and the ageing process) Broader biomedical
approach (cancer, poverty-related infectious diseases)
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Fundamental knowledge and basic tools for functional genomics
in all organisms Structural genomics LSH-2003-1.1.2-1: Comparative
structural biology of viral replication IP. The focus should be on
developing new approaches, tools and technologies for collecting
comprehensive structural information on the replicative machinery
of RNA viruses to facilitate the identification of potential new
drug targets. LSH-2003-1.1.2-2: Structure determination of large
protein complexes IP. The focus should be on the high throughput
isolation of cellular protein complexes under physiological
conditions and their structural analysis. SECOND CALL TOPICS
- Slide 10
- Fundamental knowledge and basic tools for functional genomics
in all organisms Multidisciplinary functional genomics approaches
to basic biological processes MITOCHECK (IP) Regulation of mitosis
by phosphorylation FUNGENES (IP) Functional genomics in engineered
mouse ES cells No project selected LYMPH/ANGIOGENOMICS (IP) Genome
wide discovery and functional analysis of novel genes in
lymph/angiogenesis FIRST CALL TOPICSPROJECTS FUNDED The cell cycle
Non-human embryonic stem cells Erythroid development and disorders
Lymph/angiogenesis
- Slide 11
- Epigenetics Chronic inflammation Ubiquitin-proteasome pathway
Fundamental knowledge and basic tools for functional genomics in
all organisms Multidisciplinary functional genomics approaches to
basic biological processes FIRST CALL TOPICS PROJECTS FUNDED THE
EPIGENOME (NoE) Epigenetic plasticity of the genome + The European
epigenetics network MAIN (NoE) Targeting cell migration in chronic
inflammation No project selected
- Slide 12
- Fundamental knowledge and basic tools for functional genomics
in all organisms Multidisciplinary functional genomics approaches
to basic biological processes SECOND CALL TOPICS LSH-2003-1.1.5-1:
Functional genomics approaches in animal models to study human
kidney disease IP/NOE. The focus should be on integrating different
expertise, animal models and functional genomics platforms to
discover the genetic mechanisms that underlie kidney development
and cause kidney disease. LSH-2003-1.1.5-2: Functional genomics
approaches to the study of peroxisomes in health and disease
IP/NOE. The focus should be on using functional genomics approaches
and cell and animal models to decipher the entire spectrum of
biological functions performed by peroxisomes and to evaluate their
roles in disease.
- Slide 13
- LSH-2003-1.1.5-5: DNA damage and repair mechanisms in health
and disease IP. The focus should be on using multidisciplinary
functional genomics approaches to decipher the core molecular
mechanisms of DNA damage and repair. LSH-2003-1.1.5-6: Functional
genomics approaches in animal models to study human immunological
disease IP/NOE. The focus should be on bringing together different
expertise from academic and industrial (including SMEs)
laboratories to generate a joint programme of activities that
combines research on model organisms and functional genomics to
investigate the immune system for elucidating the genetic basis of
immunological disease, thereby facilitating the development of new
diagnostics and therapeutic tools. Fundamental knowledge and basic
tools for functional genomics in all organisms Multidisciplinary
functional genomics approaches to basic biological processes SECOND
CALL TOPICS
- Slide 14
- Fundamental knowledge and basic tools for functional genomics
in all organisms Multidisciplinary functional genomics for basic
mechanisms of: Transcription activation, signal transduction,
intracellular communication, non coding genomic information,
integration of genes, in silico predicion and simulation of
regulatory networks STREPs and CAs 16 STREPs funded Low abundance
mRNAs and proteins, role of small RNAs, nanomachines, apoptosis,
comparative genomics in protozoa, standardisation, in silico
modelling of macromolecules. CA: Structuring mouse genomics and
other models, systems biology, model organisms resources, biobanks
FIRST CALL TOPICSSECOND CALL TOPICS
- Slide 15
- Application of knowledge and technologies in the field of
genomics and biotechnology for health new, safer and more effective
Rational and accelerated development of new, safer and more
effective drugs drugs including pharmacogenomics approaches new
diagnostics Development of new diagnostics new in-vitro tests
Development of new in-vitro tests to replace animal experimentation
new preventive and therapeutic tools Development and testing of new
preventive and therapeutic tools, such as somatic gene and cell
therapies (in particular stem cell therapies, for example those on
neurological and neuromuscular disorders) and immunotherapies
research in post-genomics Innovative research in post-genomics,
which has high potential for application
- Slide 16
- New drugs (6) Protein-kinases - novel drug targets (IP) Drugs
for depression (IP) Replication & integration of HIV (IP)
Individualised medicines (missing) Blood substitutes G-protein
coupled receptors European Labcourse: gene vectors (SSA)
Application of knowledge and technologies in the field of genomics
and biotechnology for health Diagnostics (2) Non-invasive advances
in prenatal diagnosis (NoE) Molecular diagnostics of kidney disease
Diagnostic for prion diseases (missing) In Vitro alternatives (3)
Hazard and risk assessment of reproductive toxicity (IP) In vitro
assays for long term toxicity Alternative methods (SSA) New
Therapies (9) European consortium for stem cell research (IP)
Allogeneic stem cell transplantation (IP) Mesenchymal stem cells
for connective tissue disorders (IP) Genome & protein
information for immune recognition Stem cells for myocardial repair
Dendritic - cells / - Vaccines / - Cancer European Labcourse:
therapy (SSA) Post Genomics (6) New approaches for autoimmune
diseases (IP) Pharmaceuticals from plants (IP) Antibiotic
resistance - Gyrase inhibitors / - Glycopeptides Genomics -
Biocatalysis Post-genomics drug discovery
- Slide 17
- Post Genomics Exploitation of fungal genomics and filamentous
fungal biotechnology for human health CA RNA as a human therapeutic
tool IP Post-genomics approach to the study of human pathogens NoE
Induction of transplant tolerance IP Novel biosafe propagation
deficient virus vectors aimed at prevention and treatment of
infectious diseases STREP New bioassays and biosensors for
detection of harmful microbes STREP FIRST CALL: New approaches for
autoimmune diseases (IP) Pharmaceuticals from plants (IP)
Antibiotic resistance - Gyrase inhibitors / - Glycopeptides
Genomics - Biocatalysis Post-genomics drug discovery SECOND CALL
Fungall cell-wall as a target of antifungal therapies STREP Use of
RNAi as tool of post-genomic analysis SSA Application of knowledge
and technologies in the field of genomics and biotechnology for
health
- Slide 18
- Priority 5 Food Quality and Safety Epidemiology of food related
diseases and allergies Epidemiology of food related diseases and
allergies Impact of food on health Traceability processes Methods
of analysis/detection and control of chemical contaminants and
pathogenic microorganisms contaminants and pathogenic
microorganisms Safer production methods and healthier foodstuffs
Impact of Animal feed on Human Health Environmental health risks
Total Food Chain
- Slide 19
- Slide 20
- strategic objectives - nutrition science benefiting from new
genomic technologies - virtual centre of excellence - transferring
acquired knowledge to stakeholders groups
- Slide 21
- process of activities Figure 1. The three concentric activities
of NuGO
- Slide 22
- integrating activities
- Slide 23
- joint research activities
- Slide 24
- activities to spread excellence Spreading of excellence
Activities Training Commercialisation Dissemination Nutrigenomics
and society The main NuGO Activities to Spread Excellence
- Slide 25
- Grain Legumes Integrated Project Grain legumes studied: pea,
bean, faba bean, chickpea, lentil and lupin (the legume Medicago
truncatula is used as a model system) Proposed budget: Total Costs:
28.153.743 Requested EC Contribution 16.961.701 (50% budget
requested by 10 partners) New strategies to improve grain legumes
for food and feed : to increase competitiveness of grain legumes in
Europe to improve Europes self-sufficiency in plant proteins 66
partners from 19 countries (~80 labs; 9 SMEs): UK; BE; BG; CH; CZ;
DE; DK; ES; FR; HU; IL; IT; NL; NO; PL; PT; SE; AU; US
- Slide 26
- Grain Legumes Integrated Project Genetic & genomic tools
food, feed & health Economic & environmental impact Seed
composition & quality Crop functioning & seed quality
Bioinformatics Coordination & training Dissemination &
transfer TTP ~10 SMEs
- Slide 27
- Cooperation and coordination of national or regional research
and innovation activities (i.e. programmes) ERA-NET ERA-NET
- Slide 28
- Participants: ERA-PG builds on national research programmes in
plant genomics (NL, AT, BE, DK, FI FR, DE, IT, NO, SP, UK). Other
states may join (BG, EE, GR, HU, IE, PO, PT, RO, SW) Objectives:
Improved co-ordinationImproved co-ordination of national plant
genomics research programmes Optimising investmentsOptimising
investments for plant genomics research and supporting policies
Creating long term perspectivesCreating long term perspectives and
improved validation of RTD strategies Means: information exchange,
web portal, short-term exchange of pgm managers, benchmarking,
joint database of experts, position papers ERA-NET co-ordination
action in plant genomics (ERA-PG)
- Slide 29
- Slide 30
- A European Strategy for Life Sciences and Biotechnology: The
Action Plan - COM (2002) 27 1. Harvesting the Potential The
resource Base investing in people generating and exploiting
knowledge intellectual property protection capital base Networking
Europes Biotechnology Communities A pro-active role for public
authorities 3. Responding to global challenge A European agenda for
international collaboration Europes responsibilities towards the
developing world 2. Governing Life Sciences and Biotechnology
Societal scrutiny and dialogue Developing Life Sciences and
Biotechnology in harmony with ethical values and social goals
Demand-driven applications through informed choice Confidence in
science-based regulatory oversight 4. Implementation and coherence
across policies, sectors and actors
- Slide 31
- TECHNOLOGY PLATFORMS European Council in March 2003 ...European
Research and Innovation Area to be strengthened to the benefit of
all in the enlarged EU by creating European technology platforms
bringing together technological know-how, industry, regulators and
financial institutions to develop a strategic agenda for leading
technologies, in areas such as plant genomics Technology Platforms
have been identified as important elements for increasing
competitiveness in the Communication Industrial policy in an
enlarged Europe (Dec. 2002) and the 3% action plan (April
2003)
- Slide 32
- 3% Action Plan: better use of public financing to increase
leverage effect on private investment; R&D in corporate
strategies and management. Progress jointly (open process of
co-ordination; European technology platforms) Improve public
support to research and innovation (human resources;
academia-industry links; mix of public financing instruments;..);
Redirect public spending towards research and innovation (refocus
public spending; state aid rules; public procurement;...)
- Slide 33
- Slide 34
- Plant Genomics SHARED PLATFORM EPSO Industry Farmers
cooperatives Biotech entrepreneurs Consumer groups Environmental
NGO Policy DGs
- Slide 35
- Improving the diagnostic and therapeutic arsenal for health
care LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
- Slide 36
- TOWARDS JOINT INDUSTRIAL PROJECTS Treaty on the European Union
Treaty on the European Union Article 171 The Community may set up
joint undertakings or any other structure necessary for the
efficient execution of Community research, technological
development and demonstration programmes E.g. GALILEO Joint
Undertaking Members are EC, ESA, EIB, private enterprises. A
tendering process is foreseen. Encompasses R&D, validation of
developments, demonstration, coordination with national activities.
Mio 5.0 to be subscribed by entrerprises, down to 250 000 for
SMEs
- Slide 37
- European Research Council Joint Industrial Projects